At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 127 enrolled
Drug / intervention
BMS-936558 (MDX1106-04) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
In Brief
A Phase 1 clinical trial evaluating BMS-936558 (MDX1106-04) and Ipilimumab for Malignant Melanoma. Completed, enrolled 127 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of treatment with BMS-936558 (MDX-1106) in combination with Ipilimumab (BMS-734016) when given at the same time or as a sequenced regimen in subjects with unresectable Stage III or Stage IV malignant melanoma (MEL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Melanoma
CountriesUnited States
CollaboratorsMedarex, Ono Pharma USA Inc
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartDec 2009
Primary CompletionFeb 2014
Study CompletionApr 2019
TodayJul 2026
First PostedDec 2, 2009
Enrollment StartDec 14, 2009
Primary CompletionFeb 4, 2014
Study CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 16.6 years ago
Interventions
BMS-936558 (MDX1106-04)drug
Ipilimumabdrug